what learnings can mrna take from the oligonucleotide regulatory paradigm?
Published 3 months ago • 24 plays • Length 3:04Download video MP4
Download video MP3
Similar videos
-
8:36
where does the mrna vaccine regulatory paradigm fall short for therapeutics?
-
3:07
the pre-ind “diaries”: what can mrna makers expect from early fda engagement?
-
10:11
how is mrna “shaking up” our regulatory interactions & operations today?
-
5:16
the fda’s “platform” provision: an emerging debate among regulators
-
10:03
the market for mrna vaccines & therapeutics
-
8:44
cmc considerations for mrna manufacturing
-
4:21
a snapshot of the rna industry & its regulatory progress
-
6:16
process development challenges in mrna therapeutics
-
5:36
oligonucleotide and mrna therapeutics with anna collén, astrazeneca
-
5:59
major advancements in mrna
-
19:51
forming up a regulatory strategy: when and how to start
-
0:54
mrna flu shot
-
27:03
the wider use of mrna to treat various forms of cancer & autoimmune diseases
-
1:20
how do mrna vaccines work?
-
0:55
doctor explains issues with mrna vaccines... #shorts
-
47:11
is rna medicine the next paradigm shift? precision nanosystems and the crs bnlf local chapter
-
21:00
translating mrna-based medicines from concept to clinic